# Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

> **NCT01095809** · PHASE3 · TERMINATED · sponsor: **Hospital Clinic of Barcelona** · enrollment: 5 (actual)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** triamcinolone acetonide

## Key facts

- **NCT ID:** NCT01095809
- **Lead sponsor:** Hospital Clinic of Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** New intraocular steroid in the market. Recruitment no longer ethical.
- **Last updated:** 2012-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01095809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01095809, "Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01095809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*